Cardiometabolic Risk reduction by rimonabant: the effectiveness in daily practice and its use.
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2013
At a glance
- Drugs Rimonabant (Primary)
- Indications Hyperglycaemia; Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CARDIO-REDUSE
- 04 Jan 2007 New trial record.